Red Glead Discovery performs integrated drug discovery. Focusing on small molecules and peptides, our drug discovery platform ranges from medicinal chemistry and synthesis to ADME and biology. The services are supported by Computational Chemistry as well as advanced MS and NMR analysis, also available as stand-alone services. Fragment-based drug discovery is an import area of expertise where we offer access for clients and partners to our proprietary technique WAC (Weak Affinity Chromatography) in combination with other FBDD techniques and methods. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients and partners that want to develop compounds with high potential to become successful drugs. Besides our CRO business, we also perform research project collaborations with various biotech and academic partners. RGD was founded in 2011 by former Astra Zeneca employees and merged with Pepticon in 2014. RGD has today over 50 co-workers. Please visit our web site or contact us directly to know more about us.